Dr Masashi Miyamoto, Director of the Board, Managing Executive Officer, Director of Corporate Strategy & Planning Department at Kyowa Hakko Kirin, explains his company’s five-year mid-term plan (2016-2020) to become a global specialty pharmaceutical company, and other significant initiatives...
List view / Grid view
Kyowa Hakko Kirin
European Pharmaceutical Review has brought you the most up-to-date and relevant pharmaceutical science for the past 21 years. This anniversary supplement brings you a selection of topical views from across the industry, reviewing progress over that time, as well as looking to the future.